# A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)

> **NCT00072969** · PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 132 (—)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Daclizumab

## Key facts

- **NCT ID:** NCT00072969
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** —
- **Final completion:** 2005-08
- **Target enrollment:** 132 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00072969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00072969, "A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00072969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*